Israeli COVID-19 Candidate Vaccine Gets Crowdfunding Support
$12m Financing Will Advance Migal Institute’s Investigational Jab
Crowd-funding venture capital platform OurCrowd is leading a $12m investment in the newly formed MigVax Corp to fund development of a potential COVID-19 vaccine whose discovery was a by-product of an avian virus vaccine researchers were already working on for the poultry industry.
You may also be interested in...
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.
Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.